Literature DB >> 27808358

Association between XRCC1 polymorphisms and laryngeal cancer susceptibility in a Chinese sample population.

W Q Wu1, L S Zhang2, S P Liao1, X L Lin1, J Zeng3, D Du4.   

Abstract

Laryngeal cancer is the major malignant tumor affecting the upper respiratory tract. Previous studies have reported on the association between XRCC1 genetic polymorphisms and risk of laryngeal cancer, but with conflicting results. In this study, we attempted to assess the association between XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphisms and risk of laryngeal cancer in a Chinese population. A total of 126 laryngeal cancer patients and 254 control subjects were recruited to this study from the Second Medical College of Jinan University between December 2013 and May 2015. The XRCC1 Arg194Trp, Arg280His, and Arg399Gln polymorphic sites were genotyped by polymerase chain reaction-restriction fragment length polymorphism. Our results revealed a significant association between the AA genotype of XRCC1 Arg280His [odds ratio (OR) = 2.51, 95% confidence interval (CI) = 1.29-4.87, P = 0.01] and an increased risk of laryngeal cancer susceptibility compared to the GG genotype. Moreover, the A allele showed a higher risk of laryngeal cancer susceptibility compared to the G allele (OR = 1.63, 95%CI = 1.19-2.50, P = 0.002). In conclusion, the results of our study suggest that the AA genotype and A allele of the XRCC1 Arg280His polymorphism are associated with an increased laryngeal cancer risk in a Chinese population.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27808358     DOI: 10.4238/gmr.15048525

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  1 in total

1.  The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo)radiotherapy in patients with nasopharyngeal carcinoma.

Authors:  Jing Wang; Chengxian Guo; Xiaochang Gong; Fan Ao; Yuling Huang; Lihua Huang; Yiqiang Tang; Chunling Jiang; Xiaoxue Xie; Qing Dong; Min Huang; Jingao Li
Journal:  Oncotarget       Date:  2017-08-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.